Takeda to Pay $2.3 million to Actos Bladder Cancer Victim
Chris Welsh, Esq.
A Philadelphia state court jury has ordered Takeda Pharmaceutical Co. to pay more than $2.3 million in damages to a plaintiff suffering bladder cancer. The plaintiff is the fifth Actos victim to be awarded damages by a jury.
Jury members found that Japan-based Takeda failed to adequately warn the plaintiff’s doctors about the drug Actos’s cancer risks. Actos, also
known as Pioglitazone, is a drug used to treat adults with type 2 diabetes and poses risk of heart failure, heart attack, and bladder cancer. Despite thousands of lawsuits, the FDA has yet to recall the drug or issue a Black Box warning. Instead, they have only updated the drug’s safety label warning. In contrast, France and Germany have both recalled the drug (drugwatch.com).
In this case, the jury also found that Takeda showed “reckless indifference” to plaintiff John Kristufek’s health by hiding risks (Bloomberg.com). They concluded that Kristufek deserved more than $300,000 for medical expenses, $2 million for pain and suffering, and will consider a punitive award. Actos still denies that Kristufek’s cancer was caused by Actos and will consider an appeal.
Reportedly, Takeda has raked in $16 billion from Actos sales since its 1999 release. Much of these winnings could be from the company’s downplaying of the drug’s risks to U.S. regulators. Whether this is true or not, the number of lawsuit speaks volumes: currently, more than 3,500 Actos suits have been consolidated in Louisiana and 4,500 in other state courts.*
If you or a loved one has suffered from complications due to the drug pioglitazone, reach out to an attorney for support. You may be able to explore legal options. Do not delay. Failing to take action may unknowingly result in losing the opportunity to bring your case due to a legal time limit, also known as the statute of limitations.
*All data on this case and Takeda shared from Jef Feeley’s report, “Takeda Ordered to Pay $2.3 Million in Damages to Actos User” on bloomberg.com.